Archifar Drug Interactions

Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion, with the effect of increasing the elimination half-life and plasma concentration of meropenem. As the potency and duration of action of Archifar dosed without probenecid are adequate, the co-administration of probenecid with Archifar is not recommended.
The potential effect of Archifar on the protein-binding of other drugs or metabolism has not been studied. The protein binding of Archifar is low (approximately 2%) and, therefore, no interactions with other compounds based on displacement from plasma proteins would be expected.
Archifar may reduce serum valproic acid levels. Subtherapeutic levels may be reached in some patients.
Archifar has been administered concomitantly with other medications without adverse pharmacological interactions. However, no specific data regarding potential drug interactions is available (apart from probenecid as previous;y mentioned).
Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60-100% decrease in valproic acid levels in about 2 days. Due to the rapid onset and the extent of the decrease, co-administration of Archifar in patients stabilised on valproic acid is not considered to be manageable and therefore should be avoided (see Precautions).
Oral Anticoagulants: Simultaneous administration of antibiotics with warfarin may augment its anticoagulant effects. There have been many reports of increases in the anticoagulant effects of orally administered anticoagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in international normalised ratio (INR) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anticoagulant agent.
Incompatibilities: Archifar must not be mixed with other medicinal products except those mentioned in Cautions for Usage.